Thank you for subscribing!
Next Investors Archived Mar 04, 2020
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.
Finfeed Archived Mar 03, 2020
Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.
Today engage:BDR's (ASX:EN1) management has provided a trading update and commentary regarding the group’s financial performance in February with a comparative analysis demonstrating significant improvements against the previous corresponding period.
Creso Pharma Limited (ASX:CPH) has signed a commercial term sheet agreement with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.
Get expert stock analysis direct in your inbox
Finfeed Archived Mar 02, 2020
Management’s take on engage:BDR's (ASX:EN1) 2020 prospects is that the company has never been positioned better for exponential revenue, profitability and market share growth.
Next Investors Archived Mar 02, 2020
MMJ Group Holdings Ltd (ASX: MMJ) is an investment company that offers a simple way for Australian investors to get exposure across a number of early stage Canadian cannabis companies with international ambitions.
NetLinkz Limited (ASX:NET) has released its half yearly report for the six months to December 31, 2019, a period that has featured a number of significant developments for the group.
Finfeed Archived Feb 28, 2020
Companies have not changed their earnings forecast, which means they do not foresee any issues arising from the coronavirus. Given this, I see no reason to sell, as many of these companies will bounce back in the not too distant future.
Antisense Therapeutics Limited (ASX:ANP) has appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.
Join Our Mailing List
